Biotron Limited · ASX:BIT
Biotron — Shareholder Meeting (October 2004)
13 slides from Biotron's shareholder meeting presentation, Oct 15, 2004
Slide 1: Presentation to Annual General Meeting cover letter
BIOTCL OM timitea A.B.N, 60 086 399 144 Level 8, 261 George Street Sydney NSW 2000 Tel: (61-2) 9247 8212 Fax: (61-2) 9247 3932 E-mail: pnightingale@biotron.com.au Website: www.biotren.com.au 15 October 2004 The Manager Companies Australian Stock Exchange Limited 20 Bridge Street SYDNEY NSW 2000 (13
Slide 2: Commentary for a presentation to the 2004 AGM
= i] & ye =r Limited A.BN. 60 086 399 144 Level 8, 261 George Street Sydney NSW 2000 Tel: (61-2) 9247 8212 Fax: (61-2) 9247 3932 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au COMMENTARY FOR A PRESENTATION TO THE 2004 AGM 15 OCTOBER 2004 The last 12 months have seen major advances i
Slide 3: Commentary continued: preclinical development and Virion expansion
Slide 6 An ongoing preclinical development program is underway to ensure the compounds' safety and efficacy, leading up to a Phase [/Ila clinical trial in humans. These steps all form part of an ordered drug development program to maximise returns to shareholders in the commercialisation of the Viri
Slide 4: Biotron AGM October 2004
BiotTtronmn AGM OCTOBER 2004
Slide 5: Virion — Unique Antiviral Platform Technology
VIRION — UNIQUE ANTIVIRAL PLATFORM TECHNOLOGY HIV - Vpu Hepatitis C virus (HCV) -p7 Coronavirus family (SARS virus) - E protein Flavivirus family (Dengue) -M protein Amiloride series New Chemical Series IT New Chemical Series IIT New Chemical Series IV Pre 2002/2003 coverage Current coverage Biotron
Slide 6: Potential Virion Market
POTENTIAL VIRION MARKET HIV Hepatitis C | SARS virus | Dengue virus virus (Coronavirus | (Flavivirus (HCV) family) family) Number of 37.8m ~4m in US ~7,600. 50m Dengue Cases worldwide (2.7m Other cases p.a. chronic coronaviruses | (15% infection); are very mortality); 170m common (e.g. >7300 cases w
Slide 7: HIV Lifecycle
Slide 8: Development of New Class of Anti-HIV Drugs
DEVELOPMENT OF NEW CLASS OF ANTI-HIV DRUGS Started with BITO09 Designed, synthesized and screened library of >160 compounds ~40 compounds had improved potency compared to BITO09 6 of the best sent overseas for confirmatory tests These 6 underwent stage | of preclinical testing — Good drug-like chara
Slide 9: Clinical development phases
on ay a idat Pee date 10n CLINICAL | _ DEVELOPMEN Phase II Phase III Phase 1V Post- marketing & _ surveillance _
Slide 10: Late Preclinical and Clinical Development of HIV Therapeutic
LATE PRECLINICAL AND CLINICAL DEVELOPMENT OF HIV THERAPEUTIC ¢ Robust development plan drawn up for next stage of preclinical development — Specific, defined milestones to meet before human trials can be started ¢ Discussions with world-renown HIV clinicians regarding human trial in progress — Ident
Slide 11: Drug Development - Pathway to Proof-of-Concept
Drug Development - Pathway to Proof-of-Concept a | | a : | | candies : _chatca _ oe “Identification | le¢niification Optimisation Preclinical _Proof of Concept _ . 1 i : Evaluation, Evaluation = a aa ax a a - Disease Target Lead Series Candidate Approval Concept Selected Selected Selected Selected f
Slide 12: C-Test Update
C-TEST UPDATE Major advances in method of detection of target molecules Great improvements in sensitivity and decreased variability Integrating software into package Working with clinicians to demonstrate role in management of disease Great deal of interest internationally in use of biomarkers for d
Slide 13: Summary
SUMMARY $2.3m cash reserves Additional $1.2m from Start and BIF grants available Sufficient resources to fund preclinical and Phase I/IIa clinical development of HIV therapeutic Focused on building strong, sustainable base under BIT, maximising returns to shareholders Biotron Limited